Dear Mr. Brann:

Please refer to your supplemental new drug applications dated March 12, 1997, received March 12, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Risperdal (risperidone) tablets and oral solution.

We acknowledge receipt of your submission dated January 28, 2002, which constituted a complete response to our January 11, 2002 action letter.

These supplemental new drug applications provide for the longer-term efficacy for risperidone in the treatment of schizophrenia.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon enclosed labeling text. We note that modifications of labeling text to more clearly state that this agent is indicated for the treatment of schizophrenia (requested in our letter of September 25, 2000) have been effected. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit the copies of final printed labeling (FPL) electronically to each application according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 20-272/S-008, 20-588/S-004." Approval of these submissions by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens must contain an assessment of the safety and effectiveness of the product in pediatric patients unless FDA waives or defers the requirement (63 FR 66632) [21 CFR 314.55]. The Agency has not made a determination if a health
benefit would be gained by studying risperidone in pediatric patients for its approved indication. FDA is deferring submission of the pediatric assessments of safety and effectiveness that may be required under these regulations until February 1, 2005.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD  20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Steven D. Hardeman, R.Ph., Senior Regulatory Project Manager, at (301) 594-5525.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Russell Katz
3/3/02 11:33:45 AM